←Back to News & Press releases Airsonett signs a new agreement: patients with severe allergic asthma in Region Västra Götaland can now receive treatment with TLA via public healthcare

Airsonett signs a new agreement: patients with severe allergic asthma in Region Västra Götaland can now receive treatment with TLA via public healthcare

September 20, 2019

Region Västra Götaland is the latest in a line of Swedish regions to sign an agreement with Air-sonett for TLA treatment. The regions Stockholm and Östergötland have previously signed similar agreements. The agreement is for prescription of the company’s unique treatment, Temperature controlled Laminar Airflow (TLA), that treats severe allergic asthma patients with particle-free air. TLA Treatment for severe asthma is part of the national guidelines for asthma treatment since 2015 and it is today prescribed to more than 600 patients in Sweden with excellent results. The number of patients treated with TLA has grown fast over the last few years.

“We are pleased that Region Västra Götaland, the second biggest region in Sweden, has now signed an agreement with Airsonett. This is further evidence that the TLA treatment has wide recognition within Swedish asthma care. We look forward to helping more patients with severe allergic asthma in additional regions”, says Anders Due-Boje, CEO Airsonett AB.

 

For more information:
Anders Due-Boje, CEO, Airsonett AB
Phone: +46 70 526 03 00
E-mail: anders.due-boje@airsonett.eu

 

About severe, uncontrolled asthma
Patients with severe, uncontrolled asthma treated according to Global Initiative for Asthma (GINA) step 4/5 account for approximately 3% of all patients with persistent asthma, according to recent population-based studies using administrative and prescribed databases, but account for a much larger share of asthma-related healthcare resource use and costs. Treatment alternatives for such patients include high-dose inhaled corticosteroids (ICS) and long-acting β2-antagonists (LABAs) and/or systematic corticosteroids. During the last decade, several new drugs for the treatment of severe asthma have been developed, and some of these drugs, such as anti-immunoglobulin E and anti-interleukin 5 have been included in Step 5 in the latest GINA recommendations. The costs for treatment with these biologics are however very high. Temperature-controlled laminar airflow (TLA) is a relatively new treatment for patients with severe, uncontrolled asthma. The use of TLA has shown cost-effectiveness according to National Institute for Health and Care Excellence (NICE) standards and the Swedish Dental and Pharmaceutical Benefits Agency, TLV, a central government agency whose remit is to determine whether a pharmaceutical product, medical device or dental care procedure shall be subsidized by the state.